Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 879,324 shares, a growth of 52.1% from the March 31st total of 577,950 shares, AnalystRatingsNetwork reports. Based on an average trading volume of 939,573 shares, the short-interest ratio is currently 0.9 days. Approximately 5.1% of the shares of the company are sold short.

Several analysts have recently commented on the stock. Analysts at TheStreet downgraded shares of Tekmira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 11th. Separately, analysts at RBC Capital initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Friday, April 11th. They set an “outperform” rating and a $30.00 price target on the stock. Finally, analysts at Maxim Group raised their price target on shares of Tekmira Pharmaceuticals from $17.00 to $31.00 in a research note on Monday, February 24th. They now have a “buy” rating on the stock.

Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 13.70 on Monday. Tekmira Pharmaceuticals has a one year low of $4.58 and a one year high of $31.48. The stock’s 50-day moving average is $19.15 and its 200-day moving average is $13.91.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.